التفاصيل البيبلوغرافية
| العنوان: |
Virological outcomes of third-line antiretroviral therapy in a global context: a systematic reviews and meta-analysis. |
| المؤلفون: |
kitaw, Tegene Atamenta, Abate, Biruk Beletew, Yilak, Gizachew, Tilahun, Befkad Derese, Faris, Abebe Merchaw, Walle, Getachew Tesfaw, Haile, Ribka Nigatu |
| المصدر: |
AIDS Research & Therapy; 6/25/2024, Vol. 21 Issue 1, p1-10, 10p |
| مصطلحات موضوعية: |
VIROLOGY, ANTIRETROVIRAL agents, VIRAL load, TREATMENT effectiveness, META-analysis, DESCRIPTIVE statistics, SYSTEMATIC reviews, MEDLINE, RNA, QUALITY of life, ONLINE information services, DATA analysis software, TREATMENT failure, PUBLICATION bias, SENSITIVITY & specificity (Statistics) |
| مستخلص: |
Background: Despite remarkable progress, HIV's influence on global health remains firm, demanding continued attention. Understanding the effectiveness of third-line antiretroviral therapy in individuals who do not respond to second-line drugs is crucial for improving treatment strategies. The virological outcomes of third-line antiretroviral therapy vary from study to study, highlighting the need for robust global estimates. Methods: A comprehensive search of databases including PubMed, MEDLINE, International Scientific Indexing, Web of Science, and Google Scholar, was conducted. STATA version 17 statistical software was used for analysis. A random-effects model was applied to compute the pooled estimates. Subgroup analysis, heterogeneity, publication bias, and sensitivity analysis were also performed. The prediction interval is computed to estimate the interval in which a future study will fall. The GRADE tool was also used to determine the quality of the evidence. Results: In this systematic review and meta-analysis, 15 studies involving 1768 HIV patients receiving third-line antiretroviral therapy were included. The pooled viral suppression of third-line antiretroviral therapy was 76.6% (95% CI: 71.5- 81.7%). The viral suppression rates at 6 and 12 months were 75.5% and 78.6%, respectively. Furthermore, third-line therapy effectively suppressed viral RNA copy numbers to ≤ 50 copies/mL, ≤ 200 copies/mL, and ≤ 400 copies/mL with rates of 70.7%, 85.4%, and 85.7%, respectively. Conclusion: More than three-fourths of patients on third-line antiretroviral therapy achieve viral suppression. Consequently, improving access to and timely initiation of third-line therapy may positively impact the quality of life for those with second-line treatment failure. Key Summary Points: Understanding the effectiveness of third-line antiretroviral therapy in individuals who do not respond to second-line drugs is crucial for improving treatment strategies. Currently, second-line treatment failure has been increasing, making progression to third-line therapy seemingly mandatory in many settings, making it apparent that recent evidence is crucial. Viral suppression rate of third-line ART was 76.6% (95% CI: 71.5- 81.7%). The viral suppression rates at 6 and 12 months were 75.5% and 78.6%. Third-line therapy effectively suppressed viral RNA copy numbers to ≤ 50 copies/mL, ≤ 200 copies/mL, and ≤ 400 copies/mL with rates of 70.7%, 85.4%, and 85.7%, respectively. [ABSTRACT FROM AUTHOR] |
|
Copyright of AIDS Research & Therapy is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder